MK
Therapeutic Areas
Amylyx Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RELYVRIO/ALBRIOZA (AMX0035) | Amyotrophic Lateral Sclerosis (ALS) | Approved/Commercial |
| AMX0035 | Amyotrophic Lateral Sclerosis (ALS) | Phase 3 |
| AMX0114 | Amyotrophic Lateral Sclerosis (ALS) | Phase 1 |
Leadership Team at Amylyx Pharmaceuticals
JC
Joshua Cohen
Co-Chief Executive Officer & Chairman of the Board
JK
Justin Klee
Co-Chief Executive Officer & President
JF
James Frates
Chief Financial Officer
MO
Margaret Olinger
Chief Commercial Officer
JM
Joseph M. Bosch
Chief Legal Officer and Corporate Secretary
CL
Camille L. Bedrosian, M.D.
Chief Medical Officer
PD
Patrick D. Yeramian, M.D.
Chief Development Officer
KD
Kelley Dupuis
Chief Operating Officer
GK
G. Kelly Martin
Board Member
DW
David W. Meline
Board Member